Brief: Sino Biopharmaceutical Discloses Exclusive License Agreement For Rovadicitinib With Sanofi
03/03/2026 22:20
March 4 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK: EXCLUSIVE LICENSE AGREEMENT FOR ROVADICITINIB WITH SANOFI GROUP IS ELIGIBLE TO RECEIVE AN UPFRONT PAYMENT OF US$135 MILLION SALES MILESTONE PAYMENTS OF UP TO US$1,395 MILLION Further company coverage: 1177.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit